RNA Therapeutics Designed for Transient Correction of Pediatric Metabolic Disorders

Abstract

RNA therapeutics represent a transformative approach in the management of pediatric metabolic disorders, offering targeted, transient correction of specific genetic and enzymatic deficiencies. This review synthesizes recent advances in RNA-based interventions for inherited metabolic diseases in children, focusing on the mechanisms, clinical applications, and future directions of such therapies. Emphasis is placed on the epidemiology, disease burden, pathophysiology, risk factors, clinical presentation, diagnostic strategies, current treatment paradigms, and the integration of RNA therapeutics within guideline-based care frameworks. The article aims to provide healthcare professionals with a comprehensive, evidence-based resource for understanding and implementing RNA therapeutics in pediatric metabolic medicine.

Introduction

Pediatric metabolic disorders, often caused by inherited mutations affecting enzymatic pathways, present significant diagnostic and therapeutic challenges. Traditional management relies on dietary modification, enzyme replacement, and supportive care, yet these approaches may be limited by incomplete efficacy and long-term complications. The advent of RNA therapeutics—particularly antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNA (mRNA) modalities—has opened new avenues for transiently correcting metabolic derangements at the molecular level. This review provides a comprehensive overview of RNA-based strategies for pediatric metabolic disorders, integrating current evidence and clinical practice considerations.

Epidemiology / Disease Burden

Inherited metabolic disorders (IMDs) constitute a diverse group of rare diseases, with a combined global incidence estimated at 1 in 800–2,500 live births. Disorders such as phenylketonuria (PKU), urea cycle defects, glycogen storage diseases, and lysosomal storage disorders are among the most prevalent. The cumulative burden extends beyond acute metabolic crises to include chronic complications—neurological, hepatic, cardiac, and skeletal—impacting quality of life and survival. Early diagnosis and intervention are critical, yet access to definitive therapies remains uneven, particularly in resource-limited settings.

Pathophysiology

Pediatric metabolic disorders typically result from single-gene mutations encoding enzymes or cofactors essential for metabolic homeostasis. Defective or deficient enzymes lead to substrate accumulation and/or toxic metabolite production, disrupting cellular function and organ integrity. RNA therapeutics target these molecular defects by modifying gene expression: ASOs can induce exon skipping or modulate splicing, siRNAs degrade pathogenic mRNA transcripts, and mRNA therapies supply functional protein templates. These interventions offer a reversible, titratable means of correcting metabolic imbalances, distinguishing them from permanent genome-editing approaches.

Risk Factors

The principal risk factor for pediatric metabolic disorders is autosomal recessive or X-linked inheritance, with heightened risk in populations with higher consanguinity rates. Family history, parental carrier status, and known genetic mutations increase the probability of disease transmission. Environmental factors may precipitate metabolic decompensation in affected individuals, including infections, fasting, or exposure to specific dietary components.

Clinical Features

Clinical manifestations vary widely, depending on the underlying disorder and enzymatic defect. Common features include failure to thrive, developmental delay, recurrent vomiting, lethargy, hepatomegaly, hypoglycemia, metabolic acidosis, and, in severe cases, coma or sudden death. Some disorders present with organ-specific symptoms, such as cardiomyopathy in Pompe disease or neurocognitive regression in mucopolysaccharidoses. Early recognition is essential for prompt intervention and prevention of irreversible damage.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, biochemical screening (e.g., plasma amino acids, urine organic acids, acylcarnitine profiles), and molecular genetic testing. Next-generation sequencing panels have revolutionized the identification of causative mutations, facilitating early detection through newborn screening programs. Functional assays and enzyme activity measurements may be required to confirm pathogenicity and guide therapeutic decisions.

Treatment & Management

Traditional management strategies include dietary restriction of offending substrates, supplementation of deficient cofactors, and enzyme replacement therapy (ERT) where available. Emergency protocols are instituted during metabolic crises to prevent catabolism and organ dysfunction. Despite advances, many patients experience suboptimal outcomes due to incomplete metabolic correction, immunogenicity, or treatment burden. RNA therapeutics offer an adjunct or alternative, aiming for precise modulation of gene expression with the potential for improved efficacy and safety.

Recent Advances / Emerging Therapies

RNA therapeutics for pediatric metabolic disorders have progressed rapidly from preclinical models to clinical trials. Notable examples include the use of siRNAs targeting hepatic gene transcripts in hyperoxaluria type 1 and hereditary transthyretin amyloidosis (with therapeutics such as lumasiran and patisiran), and ASOs modulating splicing in spinal muscular atrophy (nusinersen). mRNA-based therapies for enzyme replacement are being developed for diseases such as methylmalonic acidemia and propionic acidemia, with early studies demonstrating restoration of metabolic function in animal models. The transient nature of these interventions allows dosing flexibility, reversibility, and the opportunity to titrate therapy according to clinical response. Delivery methods—lipid nanoparticles, GalNAc conjugates, and intrathecal administration—are being refined to enhance tissue targeting and reduce off-target effects.

Guideline Recommendations

Professional societies recommend that RNA therapeutics be considered within the context of multidisciplinary care, with genetic counseling and shared decision-making. While most RNA therapies remain investigational for pediatric metabolic disorders, their use is supported by emerging consensus in cases of refractory disease or where conventional therapies are contraindicated. Ongoing surveillance for adverse effects, immunogenicity, and long-term outcomes is essential. Integration into newborn screening and early intervention frameworks may maximize clinical benefit as these therapies become more widely available.

Conclusion

RNA therapeutics represent a paradigm shift in the management of pediatric metabolic disorders, offering the promise of targeted, transient correction of underlying molecular defects. Recent advances highlight their potential to complement or replace existing therapies, especially in cases where traditional approaches are inadequate. Continued research, clinical trials, and the development of robust guideline-based frameworks will be critical in translating these innovations into routine clinical practice for affected children worldwide.